Notice of a Parallel Funding Opportunity Announcement by the Canadian Institutes of Health Research – Institute of Neurosciences, Mental Health and Addiction (CIHR-INMHA)

Notice Number: NOT-NS-19-049

Key Dates
Release Date: March 14, 2019

Related Announcements
RFA-NS-19-022

Issued by
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

On February 7, 2019, the NIH issued the following Funding Opportunity Announcement (FOA):

RFA-NS-19-022, Biological Measures for Prognosing and Monitoring of Persistent Concussive Symptoms in Early and Middle Adolescents: Center Without Walls (PCS-EMA CWOW) (U54 Clinical Trial Not Allowed)

When programmatic goals are compatible, parallel funding of a research program can have positive synergistic effects on the level and scope of research by leveraging the interests and investments of all involved agencies. Toward such goals, the Canadian Institutes of Health Research - Institute of Neurosciences, Mental Health and Addiction (CIHR-INMHA) will establish a parallel funding program to support a single research project conducted at Canadian research institutes or facilities by Canadian investigators, within the PCS-EMA CWOW (RFA-NS-19-022) selected for funding by NINDS and NICHD. CIHR-INMHA expects to provide up to $250,000 (Canadian dollars) per year for this funding opportunity. CIHR-INMHA funding is expected to supplant the equivalent amount of funds from the PCS-EMA CWOW’s award budget provided by NIH and will not change the total amount of direct costs available, as detailed in RFA-NS-19-022. This funding opportunity was published on the CIHR website by March 14, 2019.

To participate in the CIHR-INMHA parallel funding opportunity, applications to RFA-NS-19-022 with a Canadian-based research component must also submit a parallel abbreviated application to CIHR-INMHA that details the requested support for the Canadian component of the PCS-EMA CWOW (see the CIHR website for details). The Canadian component must be an integrated part of a Research Project/s in an application to RFA-NS-19-022. All PCS-EMA CWOW applications, with or without a Canadian Component, will be reviewed using a standard NIH panel review process. As such, each PCS-EMA CWOW application will be reviewed in accordance with the review criteria outlined in RFA-NS-19-022. Funds from CIHR-INMHA will only be applicable to the CWOW selected for funding by NINDS and NICHD. The NINDS, NICHD and CIHR intend to fund future years of their respective components of the awarded CWOW based on the availability of appropriations and applicable policies.

To the extent permissible under applicable laws, regulations and policies, this Canadian research team is expected to function and participate in all of the PCS-EMA CWOW activities, including involvement in the CWOW’s leadership committees and teleconferences, annual and semi-annual meetings, publications, and any additional PCS-EMA CWOW endeavors.

All applicable rules and regulations under the Freedom of Information Act (5 USC552) and Canadian Privacy Act will be followed. NIH Data Sharing Policies as outlined in NOT-OD-03-032 apply as well as TBI Clinical Research sharing policies outlined in NOT-NS-17-029.

Inquiries

Please direct all inquiries to:

Patrick Bellgowan, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1447
Email: psfb@mail.nih.gov